OrthoAccel Technologies announces commercial plans for United Kingdom

OrthoAccel Technologies, Inc. has announced commercial plans for the United Kingdom that entail considerable business activity and economic impact.  Last year, the Company hired a Director of Sales based in Wales.  Recently, a full-market UK release of the AcceleDent System was reported.  In conjunction with this product introduction at the British Orthodontic Conference, OrthoAccel has publicized plans to host a private lecture and reception to provide scientific data and education to doctors on this new technology that shortens orthodontic treatment time.

AcceleDent is a simple, removable dental device that patients place in the mouth for twenty minutes daily.  It produces a gentle vibrational force which enhances the pressure applied by braces.  AcceleDent has been clinically proven to safely speed up orthodontic tooth movement.  The product is hands-free and allows the user flexibility to carry out most routine tasks during use.  

Mike Kaufman, VP of Marketing and Business Development at OrthoAccel explained, "We really made every effort to develop an easy-to-use device that would fit into a patient's daily routine with no trouble or inconvenience."  

And patients agree that the Company has accomplished just that.

"I am usually watching television or reading journals whilst using AcceleDent," reported one adult patient, who is a physician and under the care of Dr Asif Chatoo, a London-based orthodontic specialist.  She continued, "I am extremely pleased with my orthodontic treatment and feel that AcceleDent has helped me achieve the cosmetic result I hoped for in a short time period.  I absolutely would recommend it to someone undergoing orthodontic treatment."

So now that AcceleDent, which was made available last year to a select group of orthodontic specialists, will be available to all orthodontists in the United Kingdom, what comes next?

"We view the UK as a very important strategic market," shared Mike Lowe, CEO of OrthoAccel.  "We anticipate continued investment in a country that we consider a critical entry point into the EU Region.  In addition to our sales and marketing investment, we are currently conducting analysis as to the most effective way of establishing a corporate presence and true legal entity in the UK.  Since our founding in 2007, and through our development stage, we have created a number of jobs here in the states, and the prospect of crafting economic value in other parts of the world as well is very exciting."

That value, however, is not limited to commercialization.

"We are also currently in the process of partnering with a renowned dental hospital to conduct a clinical trial in the UK as early as 2011," added Kaufman.  "We intend to build the reputation of AcceleDent and our company OrthoAccel on clinical outcome studies that add to the body of evidence based medicine. "

OrthoAccel is anticipating the conclusion of another US clinical trial at the UT Health Science Center in San Antonio with a target completion date later in 2010.  

Source:

OrthoAccel Technologies, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Age, education, and religion impact depression risk among Nigerian older adults